<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3620126</article-id><article-id pub-id-type="publisher-id">1129-2377-14-S1-P184</article-id><article-id pub-id-type="doi">10.1186/1129-2377-14-S1-P184</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Prevention of migraine by supraorbital transcutaneous neurostimulation using the Cefaly&#x000ae; device (PREMICE): a multi-centre, randomized, sham-controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Schoenen</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Vandersmissen</surname><given-names>B</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Jeangette</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Herroelen</surname><given-names>L</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Vandenheede</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Gerard</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Magis</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Headache Research Unit, Belgium</aff><aff id="I2"><label>2</label>Department of Neurology, Belgium</aff><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>21</day><month>2</month><year>2013</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Abstract Book of The European Headache and Migraine Trust International Congress</named-content><named-content content-type="supplement-editor">Peter J Goadsby and Dominique Valade</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was supported by EHMTIC Limited.</named-content></supplement><fpage>P184</fpage><lpage>P184</lpage><permissions><copyright-statement>Copyright &#x000a9;2013 Schoenen et al; licensee Springer.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Schoenen et al; licensee Springer.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.thejournalofheadacheandpain.com/content/14/S1/P184"/><conference><conf-date>20-23 September 2012</conf-date><conf-name>The European Headache and Migraine Trust International Congress</conf-name><conf-loc>London, UK</conf-loc></conference></article-meta></front><body><sec><title>Introduction</title><p>Subjects who have frequent migraine attacks (&#x02265; 2 / month) are in need of a preventive anti-migraine treatment. Available preventive drugs have incomplete efficacy and/or unpleasant side effects.</p></sec><sec><title>Purpose</title><p>Supraorbital transcutaneous neurostimulation (STNS) has shown encouraging results for migraine prevention in pilot studies and has no side effects [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. We assessed efficacy and safety of STNS in migraine prophylaxis with the Cefaly&#x000ae; device in a multicentre, double-blind, randomized, sham-controlled trial.</p></sec><sec sec-type="methods"><title>Methods</title><p>Five Belgian tertiary headache clinics participated to the study. After a 1-month run-in, patients with &#x02265; 2 migraine attacks/month were randomized to verum or sham stimulation, and applied the Cefaly&#x000ae; device daily for 20 minutes during 3 months. Primary outcome measures were change in monthly migraine days and 50% responder rate, i.e. the percentage of subjects having a &#x02265; 50% reduction of monthly migraine days. Patients and enrolling neurologists were blinded from the randomization.</p></sec><sec sec-type="results"><title>Results</title><p>Sixty-seven patients were randomized and included in the intention-to-treat analysis. Between run-in and 3rd month of treatment the mean number of migraine days decreased significantly in the verum (4.88 vs 6.94; p=0.023), but not in the sham group (6.22 vs 6.54; p=0.608). The 50% responder rate was significantly greater (p=0.023) in the verum (38.1%) than in the sham group (12.1 %). Monthly migraine attacks (p=0.044), monthly headache days (p=0.041) and monthly acute anti-migraine drug intake (p=0.007) were also significantly reduced in the verum but not in the sham group. There were no adverse events in either group.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>STNS with the Cefaly&#x000ae; device is effective as a preventive therapy for migraine. The therapeutic gain (26%) is within the range of those reported for other preventive drug and non-drug anti-migraine treatments [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>], and the safety profile is excellent.</p></sec><sec><title>Conflicts of interest</title><p>LH: Allergan. JS: ATI Redwood California, St Jude Medical USA, Allergan USA, ATI USA, Medtronic USA and Cyberonics USA.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Reed</surname><given-names>KL</given-names></name><name><surname>Black</surname><given-names>SB</given-names></name><name><surname>Banta</surname><given-names>CJ</given-names><suffix>2nd</suffix></name><name><surname>Will</surname><given-names>KR</given-names></name><article-title>Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience</article-title><source>Cephalalgia</source><year>2010</year><volume>14</volume><issue>3</issue><fpage>260</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">19732075</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Solomon</surname><given-names>S</given-names></name><name><surname>Guglielmo</surname><given-names>KM</given-names></name><article-title>Treatment of headache by transcutaneous electrical stimulation</article-title><source>Headache</source><year>1985</year><volume>14</volume><issue>1</issue><fpage>12</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1985.hed2501012.x</pub-id><pub-id pub-id-type="pmid">3871754</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>G&#x000e9;rardy</surname><given-names>PY</given-names></name><name><surname>Fabry</surname><given-names>D</given-names></name><name><surname>Fumal</surname><given-names>A</given-names></name><name><surname>Schoenen</surname><given-names>J</given-names></name><article-title>A pilot study on supra-orbital surface electrotherapy in migraine</article-title><source>Cephalalgia</source><year>2009</year><volume>14</volume><fpage>134</fpage></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Mulleners</surname><given-names>WM</given-names></name><name><surname>Chronicle</surname><given-names>EP</given-names></name><article-title>Anticonvulsants in migraine prophylaxis: a Cochrane review</article-title><source>Cephalalgia</source><year>2008</year><volume>14</volume><issue>6</issue><fpage>585</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2008.01571.x</pub-id><pub-id pub-id-type="pmid">18454787</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="other"><name><surname>Linde</surname><given-names>K</given-names></name><name><surname>Rossnagel</surname><given-names>K</given-names></name><article-title>Propranolol for migraine prophylaxis</article-title><source>Cochrane database of systematic reviews (Online)</source><year>2004</year><issue>2</issue><fpage>CD003225</fpage><pub-id pub-id-type="pmid">15106196</pub-id></mixed-citation></ref></ref-list></back></article>